XRX is officially on sale with big things in the pipeline... The current XRX share price at $0.105 is a 25% discount compared to the private placement that closed on February 28th, 2020 which was priced at $0.14.
The company has three U.S. granted patents for proprietary formulas to treat kidney disease, in addition to four U.S. patent applications for the treatment of metabolic syndrome, diabetes, fatty liver disease as well as a composition of matter patent for formulations of xanthine oxidase inhibitors.
The company's primary goal is initiation of a pivotal phase 3 clinical trial in ADPKD (Autosomal dominant polycystic kidney disease), to demonstrate the benefit of xanthine oxidase inhibition and lowering elevated uric acid as a therapy, and then commercialize by out-licensing this “first-in-class” program to a pharmaceutical partner company.
This past August the company appointed Dr. David Sans, ex-Novartis and Pfizer, as Director of Corporate Development.
https://cdn-ceo-ca.s3.amazonaws.com/1ft50u1-XORTXPLANE.jpg